

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10522134	
	Filing Date			
	First Named Inventor	Steven Jones		
	Art Unit			
	Examiner Name	Sharon L. Hurt		
	Attorney Docket Number	85084-402 MRW		

U.S. PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS				Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10522134
Filing Date		
First Named Inventor	Steven Jones	
Art Unit		
Examiner Name	Sharon L. Hurt	
Attorney Docket Number	85084-402 MRW	

1	Replication-Competent or Attenuated, Nonpropagating Vesicular Stomatitis Viruses Expressing Respiratory Syncytial Virus (RSV) Antigens Protect Mice against RSV Challenge; Jeffrey S. Kahn. et al.; Journal of Virology, Nov. 2001, p. 11079-11087; Vol. 75, No. 22	<input type="checkbox"/>
2	Development of a Preventive Vaccine for Ebola Virus Infection in Primates; Nancy J. Sullivan et al.; Letters to Nature, 2000 Macmillan Magazines Ltd., Nature/Vol 408/30 November 2000/www.nature.com, pages 605-609	<input type="checkbox"/>
3	DNA Vaccines Expressing either the GP or NP Genes of Ebola Virus Protect Mice from lethal Challenge; Lorna Vanderzanden; Virology Division, United States Army Medical Research Institute of Infectious Diseases, Ft. Detrick, Maryland 21702-5011; and PowderJect Vaccines, Inc. Madison Wisconsin 53711; Virology 246, 134-144 (1998) Article No. VY989176, pages 134-144	<input type="checkbox"/>
4	Vaccination with a Recombinant Vesicular Stomatitis Virus Expressing an Influenza Virus Hemagglutinin Provides Complete Protection from Influenza Virus Challenge; Anjeanette Roberts et al.; Journal of Virology, June 1998, p. 4704-4711; American Society for Microbiology; Vol. 72, No. 6	<input type="checkbox"/>
5	Glycoprotein Exchange Vectors Based on Vesicular Stomatitis Virus Allow Effective Boosting and Generation of Neutralizing Antibodies to a Primary Isolate of Human Immunodeficiency Virus Type 1; Nina F. Rose et al. Journal of Virology, Dec 2000, p. 10903-10910, American Society for Microbiology; Vol. 74, No. 23	<input type="checkbox"/>
6	High-Efficiency Incorporation of Functional Influenza Virus Glycoproteins into Recombinant Vesicular Stomatitis Viruses; Evelyne Kretzschmar et. al; Journal of Virology, Aug. 1997, p. 5982-5989, American Society for Microbiology, Vol. 71, No. 8	<input type="checkbox"/>
7	Towards a Vaccine Against Ebola Virus; Thomas W Geisbert et. al.; ISSN 1476-0584; Expert Rev. Vaccines 2(6), 777-789 (2003)	<input type="checkbox"/>
8	Identification of the Ebola Virus Glycoprotein as the Main Viral Determinant of Vascular Cell Cytotoxicity and Injury; Zhi_Tong Yang et al. , 2000 Nature America Inc. http://medicine.nature.com, Volume 6, Number 8, August 2000, p. 886-889	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.